June 23, 2017
Patients with refractory diabetic macular edema treated with ziv-aflibercept experienced improved visual acuity and macular thickness, with no adverse ocular or systemic side effects reported in the retrospective case series.
The case series included 34 eyes of 26 patients who had been switched to Zaltrap (ziv-aflibercept, Sanofi-Aventis/Regeneron) to treat refractory DME. All patients had previously received injections of anti-VEGF therapy. Patients received an average of 2.03 injections of ziv-aflibercept after switching treatments.